Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial

Author(s):
Reichardt, P.; Demetri, G.D.; Gelderblom, H.; Rutkowski, P.; ; Gupta, S.; Kang, Y.K.; Schoffski, P.; Schuette, J.; Soulieres, D.; Blay, J.Y.; Goldstein, D.; Fly, K.; Huang, X.; Corsaro, M.; Lechuga, M.J.; Martini, J.F.; Heinrich, M.C.
Published
2016
Publication type
Article / Letter to editor
SunitinibImatinibGISTKITKIT mutationImatinib-resistant GISTOverall survivalProgression-free survival
Date issued
2016-01-15
Language
English
Is part of
BMC Cancer
hdl
1887/112892
doi
10.1186/s12885-016-2051-5